Ad hoc releases are announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
View Featured news and Pulse updates.
Header
Newsroom
Showing 1847 results
June 2022
-
Press release
Novartis resumes production and delivery of radioligand therapy medicines ahead of schedule
Production and phased deliveries of patient doses resumed in early June Screening and enrollment have restarted for 177Lu-PSMA-617 and Lutathera® clinical trials Expanding radioligand therapy… -
Press release
New Novartis extension phase data show nearly 80% of RMS patients treated with Kesimpta® (ofatumumab) had no evidence of disease activity (NEDA-3)
New data from the Phase 3 ASCLEPIOS I/II trials and ALITHIOS open-label extension show that after four years nearly 8 out of 10 of people with relapsing multiple sclerosis (RMS) treated continuously… -
Press release
Cosentyx® (secukinumab) receives expanded approvals in EU for use in childhood arthritic conditions
Approvals based on data from the JUNIPERA trial, showing that Cosentyx® (secukinumab) reduced the risk of flare and disease activity compared to placebo over 2 years in pediatric patients1 with… -
Press release
Novartis receives positive CHMP opinion for Scemblix®, a novel treatment for adult patients with chronic myeloid leukemia
With unique STAMP mechanism of action, Scemblix could provide a new option for patients in Europe with chronic myeloid leukemia (CML) who have suffered intolerance or inadequate response with at… -
Story Access to Healthcare
Renewing our commitment to neglected tropical disease and malaria elimination
Thierry Diagana and Jonathan Spector from the Novartis Institute for Tropical Diseases (NITD) discuss learnings about their work in Neglected Tropical Diseases (NTDs) and share insights into the factors, which could lead to a resurgence of these diseases.
-
Press release
Novartis renews commitment to neglected tropical disease and malaria elimination, investing USD 250 million over five years to research and develop new treatments
Novartis endorses the Kigali Declaration on neglected tropical diseases, pledging USD 250 million to advance R&D of new treatments against NTDs and malaria over five yearsCommitment includes USD… -
Press release
Novartis Tafinlar + Mekinist receives FDA approval for first tumor-agnostic indication for BRAF V600E solid tumors
Tafinlar + Mekinist, the worldwide targeted therapy leader in BRAF/MEK-inhibition, is the first and only therapy to be approved with a tumor-agnostic indication for adult and pediatric patients with… -
Press release
Novartis receives European Commission approval for Tabrecta® for the treatment of METex14 skipping advanced non-small cell lung cancer
Tabrecta® (capmatinib) provides a new targeted therapy option for previously-treated patients in Europe who are living with advanced non-small cell lung cancer (NSCLC) harboring alterations leading… -
Ad hoc release
Novartis plans to petition the U.S. Court of Appeals for the Federal Circuit for further review to uphold validity of the Gilenya® (fingolimod) dosing regimen patent
Ad hoc announcement pursuant to Art. 53 LRBasel, June 21, 2022 — Today, Novartis announced that the U.S. Court of Appeals for the Federal Circuit (CAFC) issued a new, negative decision regarding… -
Press release
Novartis announces Nature Medicine publication of Zolgensma data demonstrating age-appropriate milestones when treating children with SMA presymptomatically
Nearly all children with two and three copies of the SMN2 gene treated presymptomatically achieved age-appropriate milestones, including sitting, standing and walking. All children were free of… -
Story Access to Healthcare
Sickle cell screening urged for newborns in Africa
Sickle cell disease disproportionately affects babies in Africa, but many go undiagnosed due to lack of screening. Newborn screening is needed to save lives and improve care.
-
Press release
Sandoz Application for proposed biosimilar adalimumab’s high concentration formulation accepted by EMA
Submission supported by comprehensive analytical and clinical data from new Phase I bridging pharmacokinetics studyAdalimumab’s high-concentration 100 mg/mL formulation aims to provide an enhanced…